NEW YORK (
CHANGE IN RATINGS
was downgraded to hold at TheStreet Ratings.
(ABBV - Get Report)
was upgraded at BMO Capital to outperform from market perform. $55 price target. Humira can drive impressive growth over the coming quarters, BMO Capital said.
(BMY - Get Report)
was upgraded at Morgan Stanley to overweight from equal-weight. $60 price target. Estimates also raised, as cancer drugs should drive growth, Morgan Stanley said.
(CHH - Get Report)
was downgraded at Robert Baird to underperform from neutral. Valuation call, based on the premium to its peers, despite a slower growth model, Robert Baird said.
Choice Hotels was upgraded at Credit Suisse to neutral from underperform. $45 price target. Company is positioned well for the current lodging cycle, Credit Suisse said.
was downgraded at Oppenheimer to perform from outperform. Company has limited earnings upside potential, Oppenheimer said.
was downgraded at Wells Fargo to market perform from outperform. Group demand outlook is softening, Wells Fargo said.
was downgraded at Deutsche Bank to hold from buy. Valuation call, based on an $83 price target, Deutsche Bank said.
(OC - Get Report)
was downgraded to hold from buy at Keybanc. Consensus earnings expectations appear too high, Keybanc said.
Owens Corning was downgraded at Bank of America/Merrill Lynch to neutral. Valuation call, based on a $40 price target, Owens Corning said. Estimates were also cut.
was upgraded at Goldman Sachs to neutral from sell. $25 price target. Valuation call, as the stock has lagged its peers in recent months, Goldman Sachs said.
was upgraded to buy at TheStreet Ratings.
was downgraded at Goldman Sachs to sell from neutral. Valuation call, based on a $50 price target, Goldman said.
T. Rowe Price
(TROW - Get Report)
was upgraded at UBS to buy from neutral. Estimates were also lifted. Outflows from the international portfolio are slowing and company is well-positioned to benefit from increasing industry inflows of active equity products, UBS said. $90 price target.
Stock Comments / EPS Changes
estimates, price target were increased at Barclays. Driven by upside potential in health exchanges and share buybacks, Barclays said. $82 price target and equal-weight rating.